Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Xie, Jing ^a   Li, Ping ^b   Gao, Hui feng ^a   Qian, Jian xin ^c   Yuan, Ling Yan ^c   Wang, Jie jun ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Immunohistochemistry; Prognostic factor; SLC38A1; Tissue microarray

Indexed keywords

CYCLINE; MEMBRANE PROTEIN; PROTEIN SLC38A1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; SLC38A1 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHINESE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; STOMACH CANCER; TISSUE MICROARRAY; TUMOR GROWTH; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AMINO ACID TRANSPORT SYSTEM A; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 84898882636     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-70     Document Type: Article

References (35)

1. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994, 299:321-334. 1138275, 8172590.
2. Lin J, Raoof DA, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, Bourner MJ, Bauer CT, Orringer MB, Beer DG. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004, 6:74-84. 10.1016/S1476-5586(04)80054-X, 1508631, 15068672.
3. Kim DK, Ahn SG, Park JC, Kanai Y, Endou H, Yoon JH. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusorlesions. Anticancer Res 2000, 24:1671-1675.
4. Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J. L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18 F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med 2007, 48:2063-2071. 10.2967/jnumed.107.043620, 18056335.
5. Campbell WA, Thompson NL. Overexpression of LAT1/CD98 light chain is sufficient to increase system L-amino acid transport activity in mouse hepatocytes but not fibroblasts. J Biol Chem 2001, 276:16877-16884. 10.1074/jbc.M008248200, 11278397.
6. Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Matsuo H, Matsubara O, Ohkura S, Yamamoto M. Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 2007, 31:81-87.
7. Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV. Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis 2007, 12:593-612. 10.1007/s10495-006-0007-y, 17195090.
8. Novak D, Quiggle F, Haafiz A. Impact of forskolin and amino acid depletion upon System A activity and SNAT expression in BeWocells. Biochimie 2006, 88:39-44. 10.1016/j.biochi.2005.07.002, 16125834.
9. Sugawara M, Nakanishi T, Fei YJ, Huang W, Ganapathy ME, Leibach FH, Ganapathy V. Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A. J Biol Chem 2000, 275:16473-16477. 10.1074/jbc.C000205200, 10747860.
10. Varoqui H, Zhu H, Yao D, Ming H, Erickson JD. Cloning and functional identification of a neuronal glutamine transporter. J Biol Chem 2000, 275:4049-4054. 10.1074/jbc.275.6.4049, 10660562.
11. Hatanaka T, Huang W, Ling R, Prasad PD, Sugawara M, Leibach FH, Ganapathy V. Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A. Biochim Biophys Acta 2001, 1510:10-17. 10.1016/S0005-2736(00)00390-4, 11342143.
12. Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J. Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer 2010, 10:428. 2928798, 20712855.
13. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829. 10.1158/1078-0432.CCR-08-2138, 19223493.
14. Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 2008, 25:695-702. 10.1007/s10585-008-9178-y, 18535914.
15. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009, 135:1331-1339. 10.1007/s00432-009-0574-8, 19337752.
16. Yu WL, Cong WM, Zhang Y, Chen Y, Wang F, Yu G. Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilarcholangiocarcinoma. J Surg Res 2011, 171:663-668.
17. Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X, Jia Z, Li Q, Xie K. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 2006, 12:6386-6394. 10.1158/1078-0432.CCR-05-2359, 17085650.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
19. Yuneva M. Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle 2008, 7:2083-2089. 10.4161/cc.7.14.6256, 18635953.
20. Viallard V, Denis C, Trocheris V, Murat JC. Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell-line HT29. Int J Biochem 1986, 18:263-269. 10.1016/0020-711X(86)90116-3, 2869987.
21. Medina MA, Sánchez-Jiménez F, Márquez J, Rodríguez-Quesada A, Nuñez-De-Castro I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 1992, 113:1-15.
22. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324. 10.1038/onc.2009.358, 2809806, 19881548.
23. Kaelin WG, Thompson CB. Q&A: Cancer: clues from cell metabolism. Nature 2010, 465:562-564. 10.1038/465562a, 20520704.
24. Weiss MD, Derazi S, Rossignol C, Varoqui H, Erickson JD, Kilberg MS, Anderson KJ. Ontogeny of the neutral amino acid transporter SAT1/ATA1 in rat brain. Brain Res Dev Brain Res 2003, 143:151-159. 10.1016/S0165-3806(03)00107-X, 12855186.
25. Berezov TT, Aptekar LS, Zinevich AK. Specificity of glutamine metabolism in pre-tumorous diseases and cancer of the human stomach. Vopr Med Khim 1977, 23:555-558.
26. Ogura M, Takarada T, Nakamichi N, Kawagoe H, Sako A, Nakazato R, Yoneda Y. Exacerbated vulnerability to oxidative stress in astrocytic C6 glioma cells with stable overexpression of the glutamine transporter slc38a1. Neurochem Int 2011, 58:504-511. 10.1016/j.neuint.2011.01.007, 21219957.
27. Bhat HK, Vadgama JV. Role of estrogen receptor in the regulation of estrogen induced amino acid transport of System A in breast cancer and other receptor positive tumor cells. Int J Mol Med 2002, 9:271-279.
28. Dudeck KL, Dudenhausen EE, Chiles TC, Fafournoux P, Kilberg MS. Evidence for inherent differences in the system A carrier from normal and transformed liver tissue. Differential inactivation and substrate protection in membrane vesicles and reconstituted proteoliposomes. J Biol Chem 1987, 262:12565-12569.
29. Okada A, Takehara H, Yoshida K, Nishi M, Miyake H, Kita Y, Komi N. Increased aspartate and glutamate levels in both gastric and colon cancer tissues. Tokushima J Exp Med 1993, 40:19-25.
30. Medina MA. Glutamine and cancer. J Nutr 2001, 131:2539S-2542S.
31. Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose?. Cancer Cell 2010, 18:199-200. 10.1016/j.ccr.2010.08.017, 2952340, 20832746.
32. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433. 10.1016/j.tibs.2010.05.003, 2917518, 20570523.
33. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: gastric cancer, V.1 2012, Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#gastric, National Comprehensive Cancer Network.
34. ZhanYQ SXW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ. Multivariate prognostic analysis in gastric carcinoma patients after radical operation. Ai Zheng 2005, 24(5):596-599.
35. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996, 32A:215-220.